Jumpstart your project with ongoing organoid screens

Colorectal
cancer

book your screen

Bladder
cancer

book your screen

KRAS
panel

book your screen

  • ATP-based cell-viability assay, with IC50 readouts
  • 3D assay format, compatible with both 96- and 384-well plate layouts.
  • Test up to 10 compounds in triplicate
  • 10-point dose-response curves per drug
  • Preset organoid panel with key driver mutations

Interested in exploring other organoid models?

Access the patient-derived organoid panel that fits your research. We leverage our vast biobank to design customized screens.

Breast
cancer

Ovarian
cancer

Lung
cancer

Pancreatic
cancer

Head & neck
cancer

Other
mutations

talk to sales

Converge cost-effectiveness with
patient-centric translational data

PDO Screen is specially crafted to prioritize speed and cost-effectiveness. Choose from our pre-set panels of patient-derived cancer organoids across multiple tissue types. Enhance your drug development process by harnessing the following benefits:

Predictivity: Identify your lead agent with the highest therapeutic potential and lowest toxicity by testing simultaneously on tumor and normal patient-derived organoids

Speed: get translatable data in a fraction of the time needed for an in vivo study

Cost saving: compared to stand-alone studies

Patient relevance: our world-leading technology recapitulates patient heterogeneity and preserves molecular and histological features of the original tumor

 

Translate your in vitro pharmacology
data from your lab to the clinic

enroll now

X

Have any questions?

contact us
PRESS RELEASE

Merck to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

learn more

Powered by